Journal for ImmunoTherapy of Cancer is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
The journal welcomes submissions in the following areas and other related topics:
Basic Tumor Immunology
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions with the anti-tumor immune response, oncolytic viruses
Clinical/Translational Cancer Immunotherapy
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combintaion therapies, cell therapies, updates on clinical trials
Immunotherapy Biomarkers
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies
Reviews/Editorials
Triggering discussion on hot topics and innovative concepts
Society affiliations
Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)
Free publication for society members
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts accepted before the end of 2013.
For more information please email info@sitcancer.org or call +414-271-2456.
Now accepting submissions
Editorial Board
Editor-in-Chief
- Prof Pedro Romero, Ludwig Center for Cancer Research, Switzerland
Section Editors
- Dr Lisa H Butterfield, University of Pittsburgh, United States of America
- Dr Bernard Fox, Earle A. Chiles Research Institute, United States of America
- Prof Thomas F Gajewski, University of Chicago, United States of America
- Dr F. Stephen Hodi, Dana-Farber Cancer Institute, United States of America
- Prof Cornelis J. Melief, Leiden University Medical Centre, Netherlands
Associate Editors
- Dr Michael B Atkins, Georgetown-Lombardi Comprehensive Care Center, United States of America
- Dr George Coukos, University of Pennsylvania Medical Center, United States of America
- Dr Mary Disis, University of Washington, United States of America
- Dr Charles Drake, Johns Hopkins University, United States of America
- Dr Lawrence Fong, University of California, San Francisco, United States of America
- Dr Elizabeth Jaffee, Johns Hopkins University, United States of America
- Dr Rejean Lapointe, Universite De Montreal, University Hospital (CRCHUM), Canada
- Dr Pamela S Ohashi, Ontario Cancer Institute, Canada
- Dr Willem Overwijk, MD Anderson Cancer Institute, United States of America
- Prof Giorgio Parmiani, Fondazione C.S. Raffaele Del Monte Tabor, Italy
- Dr Maria Rescigno, European Institute of Oncology, Italy
- Dr Nicholas P. Restifo, National Cancer Institute, United States of America
- Dr Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori, Italy
- Prof Dolores J. Schendel, Helmholtz Zentrum Munich, Germany
- Padmanee Sharma, MD Anderson Cancer Center, United States of America
- Dr Craig L Slingluff, University of Virginia, United States of America
- Dr Sjoerd H. Van der Burg, Leiden University Medical Center, Netherlands
- Dr Ena Wang, National Institutes of Health, United States of America
- Dr Cassian Yee, Fred Hutchinson Cancer Research Center, United States of America
About SITC
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The society has become THE forum for innovative discussions in the field.
Society members include nearly 600 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
SITC Mission
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.
Email updates
Receive periodic news and updates relating to this journal straight to your inbox.
